BioAv Cancer Research Results

BioAv, bioavailability: Click to Expand ⟱

Source:

Type: measurement

Bioavailability (usually in %) absorbed by the body.

Scientific Papers found: Click to Expand⟱

5464-

AF,

Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies

-

vitro+vivo,

GBM,

NA

TrxR↓, BioAv↓, ROS↑, eff↝, TET1?, BioAv↑,

5439-

AG,

Absorption enhancement study of astragaloside IV based on its transport mechanism in Caco-2 cells

-

in-vitro,

Colon,

Caco-2

BioAv↑, BioAv↓,

5356-

AL,

Therapeutic role of allicin in gastrointestinal cancers: mechanisms and safety aspects

-

Review,

GC,

NA

Apoptosis↑, TumCP↓, MAPK↓, PI3K↓, Akt↓, NF-kB↓, AntiCan↑, ChemoSen↑, TumCCA↑, Apoptosis↑, BioAv↑, selectivity↑, TGF-β↓, ROS↑, DNAdam↑, p‑P53↑, P21↑, cycD1/CCND1↓, cycE/CCNE↓, CDK4↓, CDK6↓, MMP↓, NF-kB↑, BAX↑, Bcl-2↓, ER Stress↑, Casp↑, AIF↑, Fas↑, Casp8↑, Cyt‑c↑, cl‑PARP↑, Ca+2↑, *NRF2↑, *chemoP↑, *GutMicro↑, CycB/CCNB1↑, H2S↑, HIF-1↓, RadioS↑,

1558-

Api,

Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique

-

in-vitro,

Liver,

HepG2

BioAv↑, *toxicity∅, eff↑,

3391-

ART/DHA,

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

-

Review,

Var,

NA

TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27/CDKN1B↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2/PTGS2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,

2569-

ART/DHA,

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction

-

Human,

Nor,

NA

Twenty-four healthy males

*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,

2577-

ART/DHA,

Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives

-

Review,

Var,

NA

eff↑, TumCCA↑, BioAv↑, eff↑, ChemoSen↑,

3154-

Ash,

Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults

BioAv↑, BioAv↓,

5385-

AsP,

GoldNP,

GEM,

Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery

-

in-vitro,

BC,

NA

 0.44 μg/mL

 The Au-GEM-
AsP-MOD

ROS↑, Fenton↑, BioAv↑, EPR↑,

5387-

AsP,

PacT,

Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy

-

in-vivo,

Melanoma,

B16-F10

Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,

4804-

ASTX,

Astaxanthin in cancer therapy and prevention (Review)

-

Review,

Var,

NA

-

Review,

AD,

NA

*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,

4807-

ASTX,

An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms

-

Review,

Var,

NA

*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,

5427-

ASTX,

Astaxanthin and Cancer Chemoprevention

-

Review,

Var,

NA

chemoP↑, AntiCan↑, chemoPv↑, Risk↓, lipid-P↓, Pain↓, BioAv↑, Dose↝,

5364-

AV,

A New Biomaterial Derived from Aloe vera—Acemannan from Basic Studies to Clinical Application

-

Review,

Var,

NA

BioAv↑, AntiTum↑, cardioP↑,

5568-

B-Gluc,

immuno,

Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting

-

Review,

Var,

NA

TNF-α↓, IL6↓, NF-kB↓, PD-L1↓, Imm↑, BAX↑, Bcl-2↓, TumCCA↑, angioG↓, VEGF↓, MMPs↓, OS↑, chemoP↑, eff↑, BioAv↑,

5506-

Ba,

Improved Bioavailability and Hepatoprotective Activity of Baicalein Via a Self-assembled Solutol HS15 Micelles System

-

in-vivo,

Nor,

NA

carbon tetrachloride (CCl4) induced acute liver injury.

*AST↓, *ALAT↓, *GSH↓, *SOD↓, *MDA↓, *hepatoP↑, *Inflam↓, BioAv↑,

5250-

Ba,

Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment

-

Review,

Var,

NA

Apoptosis↑, TumAuto↑, DNAdam↑, *antiOx↑, Inflam↓, PGE2↓, TumCCA↑, TumCMig↓, TumCI↓, angioG↓, selectivity↑, ChemoSen↑, HIF-1↓, cMyc↓, NF-kB↓, VEGF↓, P53↑, MMP2↓, CSCs↓, Bcl-xL↓, XIAP↓, survivin↓, tumCV↓, Casp3↑, Casp8↑, Bax:Bcl2↑, Akt↓, mTOR↓, PCNA↓, MMP↓, ROS↑, PARP↑, Casp9↑, BioAv↑, eff↑, P-gp/ABCB1↓, BioAv↑, selectivity↑,

2290-

Ba,

Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer

-

Review,

GI,

NA

p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB/CCNB1↓, cycD1/CCND1↓, cycA1/CCNA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp/ABCB1↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,

5542-

BBM,

Pharmacological profiling of a berbamine derivative for lymphoma treatment

-

vitro+vivo,

lymphoma,

NA

CaMKII ↓, TumCG↓, cMyc↓, ROS↑, UPR↑, ER Stress↑, PERK↑, BioAv↑, toxicity↓,

5550-

BBM,

docx,

Chit,

Co-Delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Enhancing Bioavailability and Anticancer Activities

-

in-vivo,

Var,

NA

eff↑, BioAv↑, Apoptosis↑, survivin↓,

2022-

BBR,

GoldNP,

Rad,

Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition

-

in-vitro,

Liver,

SMMC-7721 cell

-

in-vitro,

Nor,

HL7702

*toxicity↓, radioP↑, BioAv↑, AntiTum↑, selectivity↑, eff↑, chemoP↑,

2678-

BBR,

Berberine as a Potential Agent for the Treatment of Colorectal Cancer

-

Review,

CRC,

NA

*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2/PTGS2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,

5545-

BBR,

Improving the oral bioavailability of berberine: A crystal engineering approach

-

in-vivo,

Nor,

NA

BioAv↑,

5640-

BCA,

Improved effectiveness of biochanin A as a P-gp inhibitor in solid dispersion

-

in-vitro,

Nor,

NA

*P-gp/ABCB1↓, BioAv↑, other↝, other↑,

5634-

BCA,

Molecular Mechanisms of Biochanin A in AML Cells: Apoptosis Induction and Pathway-Specific Regulation in U937 and THP-1

-

in-vitro,

AML,

U937

-

in-vitro,

AML,

THP1

Apoptosis↑, Casp7↑, PARP1↑, Bcl-2↓, Myc↓, CHOP/DDIT3↑, P21↑, p62↑, TumCCA↑, TXNIP↑, ROS↑, *antiOx↑, *Inflam↓, *neuroP↑, AntiCan↑, TumCP↓, angioG↓, TumMeta↓, VEGF↓, MMPs↓, tumCV↓, DNAdam↑, CHOP/DDIT3↑, cMyc↓, BioAv↓, Half-Life↓, BioAv↑,

5591-

BetA,

Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment

-

Review,

BC,

NA

IC50 values ranging from 1 to 13.0 μg mL−1

BioAv↓, BioAv↑, selectivity↑, eff↑, angioG↓, *antiOx↑, *Inflam↓, MMP↓, Bcl-2↓, BAX↑, Casp9↑, Casp3↑, GRP78/BiP?, ER Stress↑, PERK↑, CHOP/DDIT3↑, ChemoSen↑, SESN2↑, ROS↑, MOMP↓, MAPK↑, Cyt‑c↑, AIF↑, STAT3↓, FAK↓, TIMP2↑, TumCMig↓, TumCI↓, Sp1/3/4↓, TumCCA↑, DNAdam↑,

5589-

BetA,

Advancements in Betulinic Acid-Loaded Nanoformulations for Enhanced Anti-Tumor Therapy

-

Review,

Var,

NA

BioAv↓, toxicity↝, BioAv↑, Half-Life↑,

5588-

BetA,

Therapeutic applications of betulinic acid nanoformulations

-

Review,

Var,

NA

BioAv↓, Half-Life↓, BioAv↑, Half-Life↑,

2735-

BetA,

Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications

-

Review,

Var,

NA

mt-Apoptosis↑, Casp↑, p38↑, MAPK↓, JNK↓, VEGF↓, AIF↑, Cyt‑c↑, ROS↑, Ca+2↑, ATP↓, NF-kB↓, ATF3↓, TOP1↓, VEGF↓, survivin↓, Sp1/3/4↓, MMP↓, ChemoSen↑, selectivity↑, BioAv↓, BioAv↑, BioAv↑, BioAv↑, BioAv↑,

2762-

BetA,

Targeting Effect of Betulinic Acid Liposome Modified by Hyaluronic Acid on Hepatoma Cells In Vitro

-

in-vitro,

Liver,

HepG2

ROCK1↓, RAS↓, *BioAv↓, BioAv↑,

5597-

Bical,

Bicalutamide: clinical pharmacokinetics and metabolism

-

Review,

Pca,

NA

Dose↝, BioAv↑, Half-Life↑, CYP3A4↓, PSA↓,

5655-

BNL,

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations

-

in-vivo,

Nor,

NA

brain pharmacokinetics after intravenous, intranasal, or oral administration

*BioAv↝, BioAv↓, BioAv↑,

5660-

BNL,

Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System

-

Review,

Var,

NA

TumMeta↓, BBB↑, EPR↑, toxicity↓, BioAv↑, ChemoSen↑, eff↑, other↑, P-gp/ABCB1↓, MDR1↓, ROS↑, TumCCA↑, other↝, BioAv↓, DNAdam↑, BioEnh↑,

5668-

BNL,

Anticancer effect of borneol: Mechanistic insights through literature review and in silico studies

-

Review,

Var,

NA

AntiCan↑, Apoptosis↑, mtDam↑, ROS↑, mTORC1↓, EIF4E↓, Hif1a↓, NF-kB↓, STAT3↓, PI3K↓, Akt↓, ChemoSen↑, BioEnh↑, BioAv↑, BBB↑, toxicity↝,

3504-

Bor,

Boron Contents of German Mineral and Medicinal Waters and Their Bioavailability in Drosophila melanogaster and Humans

-

Review,

NA,

NA

other↑, BioAv↑,

764-

Bor,

Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells

-

in-vitro,

Liver,

HepG2

BioAv↑,

2767-

Bos,

The potential role of boswellic acids in cancer prevention and treatment

-

Review,

Var,

NA

*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1/CCL2↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2/PTGS2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,

5753-

CA,

QC,

MEL,

Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction

-

in-vivo,

Colon,

Caco-2

Rats

BioAv↑, CYP1A1↓,

5825-

CAP,

Bioavailability of capsaicin and its implications for drug delivery

-

Review,

Var,

NA

-

Review,

Arthritis,

NA

-

Review,

Obesity,

NA

*AntiCan↑, *TRPV1↑, *cardioP↑, AntiCan↓, Apoptosis↑, ChemoSen↑, *Inflam↓, *Pain↓, *AntiAg↑, *Weight↓, *BioAv↑, BioAv↑, Half-Life↝, Half-Life↓,

5844-

CAP,

Non-pungent long chain capsaicin-analogs arvanil and olvanil display better anti-invasive activity than capsaicin in human small cell lung cancers

-

in-vitro,

Lung,

DMS114

eff↑, AMPK↑, toxicity↝, BioAv↑, TRPV1↑, TumCI↓,

5855-

CAP,

Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain

-

in-vivo,

Nor,

NA

NP/CIPN↓, BioAv↑, Half-Life↑, TRPV1↑, Pain↓, TRPV1↑,

2015-

CAP,

CUR,

urea,

Anti-cancer Activity of Sustained Release Capsaicin Formulations

-

Review,

Var,

NA

AntiCan↑, TumCG↓, angioG↓, TumMeta↓, BioAv↓, BioAv↓, BioAv↑, selectivity↑, EPR↑, eff↓, ChemoSen↑, Dose∅, Half-Life∅, eff↑,

5823-

capec,

Capecitabine: a review

-

Review,

CRC,

NA

eff↑, BioAv↑, eff↑,

5896-

CAR,

TV,

Carvacrol and Thymol Hybrids: Potential Anticancer and Antibacterial Therapeutics

-

Review,

Var,

NA

BioAv↑, AntiCan↑, *antiOx↑, *Inflam↑, *Bacteria↓, ROS↑, DNAdam↑,

5903-

CAR,

TV,

Combined Cytotoxic Effects of Carvacrol-Based Essential Oil Formulations

-

in-vitro,

BC,

MDA-MB-231

BioAv↑, MPT↑, ROS↑, Casp↑, eff↑, PI3K↓, Akt↓, TumCCA↑, Apoptosis↑, Cyt‑c↑, cl‑PARP↑, MPT↑,

5894-

CAR,

Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential

-

Review,

Var,

NA

AntiCan↑, Apoptosis↑, Inflam↓, angioG↓, TumMeta↓, selectivity↑, BioAv↑, ChemoSen↑, Dose↝, TumCP↓, hepatoP↑, Casp3↑, Casp9↑, Bcl-2↓, ROS↑, GSH↓, BAX↑, Casp7↑, Casp8↑, Cyt‑c↑, Fas↑, FADD↑, P53↑, Bcl-2↓, TumMeta↓, TumCMig↓, TumCI↓, E-cadherin↑, TIMP2↑, TIMP3↑, N-cadherin↓, ZEB2↓, *lipid-P↓, *AST↓, *ALAT↓, *ALP↓, *LDH↓, *SOD↑, *Catalase↑, *GPx↑, *GSR↑, selectivity↑, cl‑PARP↑, ERK↓, p38↑, OS↑, AFP↓, COX2/PTGS2↓, VEGF↓, PCNA↓, Ki-67↓, TNF-α↓, BioAv↓,

5893-

CAR,

TV,

Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management

-

Review,

Var,

NA

*Inflam↓, AntiCan↑, PI3K↓, Akt↓, mTOR↓, NOTCH↓, PIK3CA↓, EGFR↓, Hif1a↓, VEGF↓, ChemoSen↑, RadioS↑, eff↝, *cardioP↑, *neuroP↑, *hepatoP↑, Apoptosis↑, MMP↓, Casp3↑, ROS↑, DNAdam↑, eff↑, BAX↑, BAD↑, FasL↑, Cyt‑c↑, Casp9↑, Casp8↑, TumCCA↑, P21↑, Smo↓, Gli1↓, JNK↑, ERK↓, MAPK↓, TRPM7↓, Wnt/(β-catenin)↓, BioAv↝, BioAv↑,

5928-

Catechins,

Bioavailability of Tea Catechins and Its Improvement

-

Review,

Nor,

NA

*BioAv↝, *BioAv↓, *ROS⇅, *NRF2↑, *BioAv↑, *Half-Life↓, *BioAv↑, *BioAv↑, BioAv↑,

6254-

CBC/D,

Cynanchum auriculatum Royle ex Wight., Cynanchum bungei Decne. and Cynanchum wilfordii (Maxim.) Hemsl.: Current Research and Prospects

-

Review,

Var,

NA

*neuroP↑, *Imm↑, *Inflam↓, CSCs↓, HH↓, Gli↓, AST↓, ALAT↓, MDA↓, hepatoP↑, *NRF2↑, *HO-1↑, NF-kB?, GSK‐3β↓, β-catenin/ZEB1↓, COX2/PTGS2↓, MMP2↑, MMP9↓, BioAv↑,

5813-

CBD,

Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis

-

Review,

Var,

NA

Dose↝, BioAv↑, BioAv↓, BioAv↑,

Showing Research Papers: 1 to 50 of 205
Page 1 of 5 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 205

Pathway results for Effect on Cancer / Diseased Cells:

NA, unassigned(tgid=0) ⓘ

p‑AMT/GCST/T-protein↑, 1, APE1/APEX1↓, 1, CUL1↝, 1, CUL5↝, 1, CX43/GJA1↓, 1, DDIT4↑, 1, ENL↑, 1, HLA-I/II↑, 1, IGF-2R↑, 1, miR-106b↓, 1, miR-375↑, 1, NOD1↓, 1, PFS↓, 1, PGI2↓, 1,

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1, antiOx↑, 9, ARE↓, 1, ATF3↓, 1, Catalase↓, 2, Catalase↑, 1, compI↓, 1, CYP1A1↓, 3, Fenton↑, 2, Ferroptosis↑, 3, GPx↓, 1, GPx↑, 2, GPx4↓, 1, GSH↓, 8, GSH↑, 2, GSH/GSSG↓, 1, GSR↓, 2, GSR↑, 1, ox-GSSG↑, 1, GSTA1↑, 2, GSTs↓, 1, GSTZ1↓, 1, e-H2O2↓, 1, i-H2O2∅, 1, HO-1↓, 2, HO-1↑, 5, Iron↑, 1, i-Iron↑, 1, lipid-P?, 1, lipid-P↓, 3, lipid-P↑, 4, MDA↓, 1, MDA↑, 1, NQO1↓, 1, NQO1↑, 1, NRF2↓, 7, NRF2↑, 8, OXPHOS↓, 2, OXPHOS↑, 1, mt-OXPHOS↓, 1, PARK2↑, 1, Prx↓, 1, Prx4↑, 1, PrxII↓, 1, ROS↓, 7, ROS↑, 87, ROS⇅, 4, SOD↓, 2, SOD↑, 2, SOD1↓, 2, SOD2↓, 1, Trx↓, 1, TrxR↓, 5, VitC↓, 1, VitE↓, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

Tf↓, 1, TfR1/CD71↑, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

ABL1↓, 1, ADP:ATP↑, 2, AIF↑, 6, ATP↓, 6, ATP↑, 1, mt-ATP↓, 1, CDC2↓, 1, CDC25↓, 1, EGF↓, 1, ETC↑, 1, MEK↓, 1, MMP↓, 24, MMP↑, 2, MPT↑, 4, mtDam↑, 4, OCR↓, 1, OCR↑, 1, PINK1↑, 1, Raf↓, 2, SDH↑, 1, XIAP↓, 7,

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1, ALAT↓, 3, ALAT↑, 1, ALDOA↓, 1, AMPK↑, 4, AMPK↝, 1, cMyc↓, 10, cMyc↑, 1, CRM↝, 1, CYP3A4↓, 1, ECAR↓, 2, ENO1↓, 1, FASN↓, 2, GAPDH↓, 1, GLO-I↓, 1, glucose↓, 1, GlucoseCon↓, 6, Glycolysis↓, 17, H2S↑, 1, HK2↓, 7, HMG-CoA↓, 1, lactateProd↓, 7, lactateProd↑, 1, LDH↓, 2, LDHA↓, 2, LDL↓, 2, lipoGen↓, 1, MCT4↓, 2, NADH:NAD↓, 1, NADPH↓, 1, PDK1 / PDPK1↓, 5, PDK3↑, 1, PFK1↓, 1, PIK3CA↓, 1, PKM2↓, 5, PPARα↓, 2, PPARγ↑, 1, SIRT1↓, 1, SIRT1↑, 4, TCA↑, 1, Warburg↓, 4,

Cell Death(tgid=5) ⓘ

Akt↓, 35, Akt↑, 3, p‑Akt↓, 11, APAF1↑, 1, Apoptosis↓, 2, Apoptosis↑, 56, mt-Apoptosis↑, 2, BAD↓, 1, BAD↑, 2, Bak↑, 1, BAX↓, 1, BAX↑, 26, Bax:Bcl2↓, 1, Bax:Bcl2↑, 5, Bcl-2↓, 28, Bcl-2↑, 2, Bcl-xL↓, 9, BID↓, 1, Casp↑, 12, Casp1↓, 1, Casp3↓, 1, Casp3↑, 34, cl‑Casp3↑, 5, Casp7↑, 7, cl‑Casp7↑, 1, Casp8↑, 16, cl‑Casp8↑, 1, proCasp8↑, 1, pro‑Casp8↑, 1, Casp9↓, 1, Casp9↑, 23, cl‑Casp9↑, 3, CBP↓, 1, cFLIP↓, 1, Chk2↓, 1, Cyt‑c↓, 1, Cyt‑c↑, 17, Cyt‑c↝, 1, DR4↑, 2, DR5↑, 5, FADD↑, 2, Fas↑, 4, FasL↑, 3, Ferroptosis↑, 3, GranB/GZMB↓, 1, HGF/c-Met↓, 1, hTERT/TERT↓, 7, IAP1↓, 2, IAP2/BIRC3↓, 1, IAP2/BIRC3↑, 1, iNOS↓, 2, JNK↓, 2, JNK↑, 7, p‑JNK↑, 2, MAPK↓, 16, MAPK↑, 4, Mcl-1↓, 5, MCT1↓, 2, MDM2↓, 2, MDM2↑, 1, p‑MDM2↓, 1, MOMP↓, 1, MOMP↑, 2, Myc↓, 3, necrosis↑, 2, NOXA↑, 1, p27/CDKN1B↑, 6, p38↑, 6, p‑p38↑, 2, Proteasome↓, 1, survivin↓, 13, Telomerase↓, 4, TRAIL⇅, 1, TRAILR↑, 1, TRPV1↑, 3, TumCD↓, 1, TumCD↑, 5, YAP/TEAD↓, 1,

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 1, FOXD3↑, 1, HER2/EBBR2↓, 1, SOX9?, 1, Sp1/3/4↓, 4,

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↑, 1, EZH2↓, 1, H3↓, 1, H4↓, 1, HATs↓, 1, miR-21↓, 3, miR-218↑, 1, miR-27a-3p↓, 1, miR-30a-5p↑, 1, other↑, 8, other↝, 16, PhotoS↑, 2, SD↑, 1, sonoS↑, 1, tumCV↓, 9,

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1, CHOP/DDIT3↑, 10, eIF2α↑, 2, p‑eIF2α↑, 2, ER Stress↓, 1, ER Stress↑, 17, GRP78/BiP?, 1, GRP78/BiP↓, 2, GRP78/BiP↑, 3, GRP78/BiP↝, 1, HSP70/HSPA5↑, 1, HSP90↓, 3, PERK↑, 5, UPR↑, 5, XBP-1↓, 1, XBP-1↑, 1,

Autophagy & Lysosomes(tgid=9) ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1, LC3II↓, 1, LC3II↑, 1, p62↑, 1, SESN2↑, 2, TumAuto↑, 10, TumAuto⇅, 1, TumAuto↝, 1,

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1, DNAdam↓, 2, DNAdam↑, 20, DNMT1↓, 2, DNMT3A↓, 1, DNMTs↓, 2, p16↑, 1, P53↓, 1, P53↑, 20, p‑P53↑, 1, p53 Wildtype↓, 1, p53 Wildtype↑, 1, PARP↑, 5, cl‑PARP↓, 2, cl‑PARP↑, 20, PARP1↑, 1, PCNA↓, 6, TP53↑, 3, γH2AX↓, 1, γH2AX↑, 1,

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 4, CDK1↑, 1, CDK2↓, 10, CDK4↓, 14, cycA1/CCNA1↑, 1, CycB/CCNB1↓, 7, CycB/CCNB1↑, 3, cycD1/CCND1↓, 22, cycD1/CCND1↑, 1, CycD3↓, 1, cycE/CCNE↓, 7, E2Fs↓, 2, P21↑, 17, p‑RB1↓, 3, TumCCA↓, 3, TumCCA↑, 54,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 3, ALDH1A1↓, 1, CD133↓, 2, CD34↓, 1, CD44↓, 2, p‑cDC2↓, 1, cFos↑, 1, CIP2A↓, 1, CSCs↓, 18, CTNNB1↓, 1, Diff↑, 2, EIF4E↓, 1, EMT↓, 24, ERK↓, 11, ERK↑, 2, p‑ERK↓, 5, FOXM1↓, 1, FOXO1↑, 1, FOXO4↑, 1, Gli↓, 1, Gli1↓, 4, GSK‐3β↓, 4, GSK‐3β↑, 1, HDAC↓, 9, HDAC10↓, 1, HDAC2↓, 1, HH↓, 6, IGF-1↓, 1, Let-7↑, 2, miR-34a↑, 2, mTOR↓, 23, mTOR↝, 1, p‑mTOR↓, 3, mTORC1↓, 1, Nanog↓, 3, NOTCH↓, 7, NOTCH1↓, 3, NOTCH1↑, 3, OCT4↓, 3, p300↓, 1, p‑P70S6K↓, 1, PI3K↓, 31, PI3K↑, 1, p‑PI3K↓, 3, PTCH1↓, 1, PTEN↓, 1, PTEN↑, 12, RAS↓, 4, Shh↓, 2, SHP1↑, 1, Smo↓, 1, SOX2↓, 2, Src↓, 2, p‑Src↓, 1, STAT1↓, 1, STAT3↓, 23, STAT3↑, 2, p‑STAT3↓, 4, STAT6↓, 2, p‑STAT6↓, 1, TOP1↓, 6, TOP2↓, 1, TOP2↑, 1, TRPM7↓, 1, TumCG↓, 19, tyrosinase↓, 1, Wnt↓, 11, Wnt/(β-catenin)↓, 1,

Migration(tgid=13) ⓘ

5LO↓, 2, AP-1↓, 4, AXL↓, 1, Ca+2↑, 6, Ca+2↝, 1, CD31/PECAM-1↓, 1, Cdc42↓, 1, Cdc42↑, 1, CEA↓, 1, CLDN1↓, 2, CLDN1↑, 1, CXCL12↓, 1, E-cadherin↓, 3, E-cadherin↑, 8, FAK↓, 5, FAK↑, 1, p‑FAK↓, 2, Fibronectin↓, 1, ITGB1↓, 1, Ki-67↓, 8, KRAS↓, 1, LAMs↓, 1, MET↓, 1, p‑MET↓, 1, miR-19b↓, 2, miR-200b↑, 1, MMP-10↓, 1, MMP1↓, 2, MMP2↓, 22, MMP2↑, 1, MMP3↓, 1, MMP7↓, 2, MMP9↓, 30, MMP9↑, 1, MMPs↓, 12, MUC4↓, 2, N-cadherin↓, 4, PDGF↓, 1, PKA↓, 1, PKCδ↓, 2, Rac1↓, 2, Rho↓, 3, ROCK1↓, 3, Slug↓, 3, Snail↓, 4, SOX4↑, 1, TET1?, 1, TET1↑, 4, TGF-β↓, 3, TIMP1↑, 4, TIMP2↑, 5, TIMP3↑, 1, TJ↓, 1, TJ↑, 1, TRIB3↑, 1, TumCA↓, 2, TumCI↓, 19, TumCMig↓, 18, TumCP↓, 42, TumCP↑, 1, TumMeta↓, 34, TumMeta↑, 3, Twist↓, 6, TXNIP↑, 1, Tyro3↓, 1, uPA↓, 4, VEGFR1↓, 1, Vim↓, 5, Vim↑, 1, Zeb1↓, 1, ZEB2↓, 1, ZO-1↑, 2, α-SMA↓, 1, α-tubulin↓, 1, β-catenin/ZEB1↓, 10, β-catenin/ZEB1↑, 1,

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 52, ATF4↑, 3, ATF4↝, 1, EGFR↓, 6, EGFR↑, 1, Endoglin↑, 1, EPR↑, 9, HIF-1↓, 5, Hif1a↓, 20, NO↓, 1, p‑PDGFR-BB↓, 1, VEGF↓, 41, VEGFR2/KDR/Flk1↓, 1, ZBTB10↑, 1,

Barriers & Transport(tgid=15) ⓘ

BBB↑, 8, GLUT1↓, 3, GLUT4↓, 1, IBI↑, 1, OCLN↑, 1, P-gp/ABCB1↓, 6, P-gp/ABCB1↑, 2,

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1, COX2/PTGS2↓, 22, COX2/PTGS2↑, 2, CRP↓, 1, CXCR4↓, 3, HCAR1↓, 1, ICAM-1↓, 3, IKKα↓, 2, p‑IKKα↓, 1, IL1↓, 1, IL1↑, 1, IL10↓, 2, IL10↑, 1, IL1α↓, 1, IL1β↓, 6, IL2↓, 2, IL2↑, 3, IL4↑, 1, IL6↓, 16, IL8↓, 2, Imm↑, 8, Imm↝, 2, INF-γ↓, 1, Inflam↓, 19, IκB↓, 1, IκB↑, 1, JAK1↓, 1, JAK1↑, 1, JAK2↓, 2, p‑JAK2↓, 1, MCP1/CCL2↓, 1, MIP‑1α/CCL3↓, 1, MIP2↓, 1, NF-kB?, 1, NF-kB↓, 49, NF-kB↑, 1, NK cell↑, 2, p65↓, 2, p‑p65↓, 2, PD-1↓, 2, PD-L1↓, 4, PGE1↓, 1, PGE2↓, 9, PSA↓, 5, SOCS-3↓, 1, TLR4↓, 3, TNF-α↓, 16, TNF-α↑, 1,

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1, e-pH↑, 2, i-pH↓, 1,

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1, NLRP3↑, 1, PP2A↑, 1,

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 8, CDK6↓, 4, COMT↓, 2, CYP19↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 66, BioAv↑, 229, BioAv↝, 10, BioEnh↑, 5, chemoR↓, 1, ChemoSen↑, 67, ChemoSen⇅, 1, CYP17A1↓, 1, DDS↑, 8, Dose↓, 1, Dose↑, 7, Dose↝, 31, Dose∅, 3, DrugR↓, 1, eff↓, 14, eff↑, 109, eff↝, 4, Half-Life↓, 13, Half-Life↑, 10, Half-Life↝, 12, Half-Life∅, 2, MDR1↓, 5, MRP1/ABCC1↓, 2, P450↓, 1, RadioS↑, 29, selectivity↑, 30, selectivity∅, 1,

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 1, ALAT↓, 3, ALAT↑, 1, ALP↓, 2, AR↓, 8, ascitic↓, 1, AST↓, 2, AST↑, 1, BMD↑, 1, CEA↓, 1, CEC↝, 1, CRP↓, 1, EGFR↓, 6, EGFR↑, 1, EZH2↓, 1, FOXM1↓, 1, GutMicro↑, 7, HER2/EBBR2↓, 1, hTERT/TERT↓, 7, IL6↓, 16, Ki-67↓, 8, KRAS↓, 1, LDH↓, 2, Myc↓, 3, NOS2↓, 1, NSE↓, 1, PD-L1↓, 4, PSA↓, 5, TP53↑, 3, TRIB3↑, 1,

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 2, AntiCan↓, 3, AntiCan↑, 28, AntiDiabetic↑, 1, antiNeop↑, 1, AntiTum↑, 9, cachexia↓, 1, cardioP↑, 8, CardioT↓, 1, CardioT↑, 1, chemoP↑, 15, chemoPv↑, 7, ChemoSideEff↓, 1, fatigue↓, 1, hepatoP↓, 2, hepatoP↑, 4, memory↑, 1, neuroP↑, 6, NP/CIPN↓, 1, OS↑, 9, Pain↓, 2, QoL↑, 2, radioP↑, 2, RenoP↑, 1, Risk↓, 6, toxicity↓, 17, toxicity↑, 4, toxicity⇅, 2, toxicity↝, 13, toxicity∅, 3, TumVol↓, 5, TumW↓, 2, Weight↑, 1, Wound Healing↑, 2,

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1, Sepsis↓, 1,
Total Targets: 608

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 6, antiOx↑, 29, ARE↑, 1, Catalase↑, 6, GPx↑, 5, GSH↓, 1, GSH↑, 4, GSR↑, 2, GSTs↑, 3, H2O2↑, 1, HNE↓, 1, HO-1↑, 7, lipid-P↓, 6, MDA↓, 6, NQO1↑, 1, Nrf1↑, 1, NRF2↑, 7, RNS↓, 1, ROS↓, 29, ROS⇅, 1, SOD↓, 2, SOD↑, 9, SOD1↑, 1, VitC↑, 2, VitE↑, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2, CREB↑, 1, LDH↓, 2, lipidLev↓, 1,

Cell Death(tgid=5) ⓘ

Akt↓, 1, Akt↑, 1, Apoptosis↓, 1, Casp3↓, 2, Casp9↓, 1, iNOS↓, 1, JNK↓, 1, p‑JNK↓, 1, MAPK↑, 1, p38↓, 1, Pyro↓, 1, TRPV1↑, 1,

Transcription & Epigenetics(tgid=7) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1, LC3II↓, 1,

DNA Damage & Repair(tgid=10) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1, HDAC↓, 1, HDAC3↓, 1, IGF-1↓, 1, IGFBP3↑, 1, neuroG↑, 1, PI3K↓, 1, STAT↓, 1,

Migration(tgid=13) ⓘ

AntiAg↑, 3, Ca+2↝, 1, Ki-67↓, 1, PKCδ↑, 1,

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2, IL10↑, 1, IL1β↓, 3, IL2↓, 1, IL6↓, 3, IL8↓, 1, Imm↑, 3, Imm⇅, 1, Inflam?, 1, Inflam↓, 34, Inflam↑, 1, NF-kB↓, 8, TLR3↓, 1, TNF-α↓, 6,

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1, AChE↓, 1, GABA↑, 1, MAOA↓, 1, tau↓, 1, p‑tau↓, 1,

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1, BACE/β-secretase↓, 1, NLRP3↓, 3, NLRP3↑, 1, XO↝, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv?, 1, BioAv↓, 12, BioAv↑, 11, BioAv↝, 5, Dose↝, 1, eff↑, 2, Half-Life↓, 3, Half-Life↑, 1, Half-Life↝, 5, Half-Life∅, 1, P450↑, 1,

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2, ALP↓, 1, AST↓, 3, BG↓, 1, GutMicro↑, 3, IL6↓, 3, Ki-67↓, 1, LDH↓, 2,

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 3, AntiArt↑, 1, AntiCan↑, 5, AntiDiabetic↑, 5, antiPs↑, 1, AntiTum↓, 2, AntiTum↑, 1, cardioP↑, 13, CardioT↓, 1, chemoP↑, 2, chemoPv↑, 2, cognitive↑, 4, hepatoP↑, 8, memory↑, 4, motorD↓, 1, neuroP↓, 2, neuroP↑, 19, Pain↓, 1, radioP↑, 1, RenoP↑, 2, toxicity↓, 9, toxicity↑, 1, toxicity↝, 3, toxicity∅, 2, Weight↓, 1, Wound Healing↑, 1,

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 2, Bacteria↓, 6,
Total Targets: 134

Scientific Paper Hit Count for: BioAv, bioavailability

13 Curcumin
11 chitosan
7 Chrysin
7 Pterostilbene
5 Betulinic acid
5 Capsaicin
5 Sulforaphane (mainly Broccoli)
4 borneol
4 Quercetin
4 Carvacrol
4 Kaempferol
4 Luteolin
4 Lycopene
4 Piperlongumine
4 Thymoquinone
3 Artemisinin
3 Astaxanthin
3 Baicalein
3 Berberine
3 Thymol-Thymus vulgaris
3 EGCG (Epigallocatechin Gallate)
3 Gallic acid
3 Gossypol/AT-101
3 Honokiol
3 Isoliquiritigenin
3 Lecithin
3 Naringin
3 Phenylbutyrate
3 Resveratrol
3 Rosmarinic acid
3 Urolithin
2 Ascorbyl Palmitate
2 Gold NanoParticles
2 immunotherapy
2 Berbamine
2 Docetaxel
2 Radiotherapy/Radiation
2 Biochanin A
2 Boron
2 Celastrol
2 Camptothecin
2 Cucurbitacin
2 Disulfiram
2 Eugenol
2 Fisetin
2 Fucoidan
2 Glabrescione B
2 Grapeseed extract
2 isoquercitrin
2 Niclosamide (Niclocide)
2 Phenethyl isothiocyanate
2 Vitamin C (Ascorbic Acid)
1 Auranofin
1 Astragalus
1 Allicin (mainly Garlic)
1 Apigenin (mainly Parsley)
1 Ashwagandha(Withaferin A)
1 Gemcitabine (Gemzar)
1 Paclitaxel/Taxol
1 Aloe anthraquinones
1 beta-glucans
1 Bicalutamide
1 Boswellia (frankincense)
1 Caffeic acid
1 Melatonin
1 urea
1 capecitabine
1 Catechins
1 Cynanbungeigenin C (CBC) and D (CBD)
1 Cannabidiol
1 Choline
1 Rutin
1 Propolis -bee glue
1 Cinnamon
1 Coenzyme Q10
1 irinotecan
1 Crocetin
1 Dichloroacetophenone(2,2-)
1 Dasatinib/Phyrago
1 Dichloroacetate
1 Deguelin
1 Diclofenac
1 Copper and Cu NanoParticles
1 Ellagic acid
1 Emodin
1 Electrical Pulses
1 Evodiamine
1 Ferulic acid
1 Fenbendazole
1 Shilajit/Fulvic Acid
1 Gambogic Acid
1 Garcinol
1 Germanium Organic/Ge-132 / propagermanium (organogermanium)
1 Genistein (soy isoflavone)
1 Ginkgolide B
1 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
1 isoflavones
1 itraconazole
1 Lapatinib
1 Licochalcone A
1 SDG/lignans
1 Folic Acid, Vit B9
1 magnetic nanoparticles
1 Magnetic Fields
1 Bicarbonate(Sodium)
1 Oxygen, Hyperbaric
1 Psoralidin
1 Parthenolide
1 Selenium
1 Selenium NanoParticles
1 Chemotherapy
1 Silymarin (Milk Thistle) silibinin
1 Spermidine
1 Aflavin-3,3′-digallate
1 Turmerones
1 Vitamin K2

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:792  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

Home Page